Univariable analysis of factors associated with syngeneic GVHD
Factor . | No. . | GVHD incidence, No. (%) . | HR . | 95% Cl . | Level-specific P value, > 2 levels . | Overall P value, log-rank test . |
|---|---|---|---|---|---|---|
| Age, y | ||||||
| 16 to 39 | 50 | 3 (6) | 1.0 | Reference | NA | |
| 40 to 68 | 69 | 18 (26) | 5.0 | 1.5-16.8 | NA | < .01 |
| Sex | ||||||
| Male | 70 | 9 (13) | 1.0 | Reference | NA | |
| Female | 49 | 12 (24) | 2.0 | 0.8-4.8 | NA | .11 |
| Donor parity, N = 115 | ||||||
| Nulliparous | 11 | 1 (9) | 1.0 | Reference | Reference | |
| Parous | 34 | 11 (32) | 4.6 | 0.6-35.9 | .07 | |
| Male | 70 | 9 (13) | 1.7 | 0.2-13.1 | .61 | .03 |
| Recipient parity | ||||||
| Nulliparous | 14 | 1 (7) | 1.0 | Reference | Reference | |
| Parous | 35 | 11 (31) | 6.0 | 0.8-46.2 | .03 | |
| Male | 70 | 9 (13) | 2.1 | 0.3-16.5 | .44 | .02 |
| CMV serostatus | ||||||
| Donor serostatus, N = 76 | ||||||
| Negative | 37 | 8 (22) | 1.0 | Reference | NA | |
| Positive | 41 | 11 (27) | 1.4 | 0.5-3.4 | NA | .51 |
| Recipient serostatus, N = 105 | ||||||
| Negative | 46 | 6 (13) | 1.0 | Reference | NA | |
| Positive | 57 | 15 (26) | 2.3 | 0.9-6.1 | NA | .07 |
| Acute lymphocytic leukemia | ||||||
| No | 112 | 18 (16) | 1.0 | Reference | NA | |
| Yes | 7 | 3 (43) | 2.7 | 0.8-9.2 | NA | .10 |
| HLA-A26, N = 117 | ||||||
| No | 111 | 18 (16) | 1.0 | Reference | NA | |
| Yes | 6 | 3 (50) | 3.6 | 1.0-12.2 | NA | .03 |
| HLA-DR2, N = 90 | ||||||
| No | 60 | 10 (17) | 1.0 | Reference | NA | |
| Yes | 30 | 9 (30) | 1.8 | 0.7-4.4 | NA | .19 |
| Cell source | ||||||
| PBSC | 31 | 8 (26) | 1.0 | Reference | NA | |
| Bone marrow | 88 | 13 (15) | 0.5 | 0.2-1.3 | NA | .15 |
| Donor buffy coat infusion | ||||||
| No | 87 | 18 (21) | 1.0 | Reference | NA | |
| Yes | 32 | 3 (9) | 0.5 | 0.1-1.5 | NA | .19 |
| Immunotherapy | ||||||
| No | 108 | 17 (16) | 1.0 | Reference | NA | |
| Yes | 11 | 4 (36) | 2.5 | 0.9-7.6 | NA | .08 |
| IL-2 therapy | ||||||
| No | 112 | 18 (16) | 1.0 | Reference | NA | |
| Yes | 9 | 4 (44) | 3.5 | 1.2-10.3 | NA | .02 |
| Conditioning regimen | ||||||
| Non-BUMELT | 107 | 16 (15) | 1.0 | Reference | NA | |
| BUMELT | 12 | 5 (42) | 3.6 | 1.3-9.8 | NA | < .01 |
| Transplantation year | ||||||
| 1980 to 1987 | 58 | 3 (5) | 1.0 | Reference | Reference | |
| 1988 to 1995 | 43 | 12 (28) | 5.2 | 1.5-18.6 | < .01 | |
| 1996 to 2002 | 18 | 6 (33) | 7.5 | 1.9-30.1 | < .01 | < .01 |
Factor . | No. . | GVHD incidence, No. (%) . | HR . | 95% Cl . | Level-specific P value, > 2 levels . | Overall P value, log-rank test . |
|---|---|---|---|---|---|---|
| Age, y | ||||||
| 16 to 39 | 50 | 3 (6) | 1.0 | Reference | NA | |
| 40 to 68 | 69 | 18 (26) | 5.0 | 1.5-16.8 | NA | < .01 |
| Sex | ||||||
| Male | 70 | 9 (13) | 1.0 | Reference | NA | |
| Female | 49 | 12 (24) | 2.0 | 0.8-4.8 | NA | .11 |
| Donor parity, N = 115 | ||||||
| Nulliparous | 11 | 1 (9) | 1.0 | Reference | Reference | |
| Parous | 34 | 11 (32) | 4.6 | 0.6-35.9 | .07 | |
| Male | 70 | 9 (13) | 1.7 | 0.2-13.1 | .61 | .03 |
| Recipient parity | ||||||
| Nulliparous | 14 | 1 (7) | 1.0 | Reference | Reference | |
| Parous | 35 | 11 (31) | 6.0 | 0.8-46.2 | .03 | |
| Male | 70 | 9 (13) | 2.1 | 0.3-16.5 | .44 | .02 |
| CMV serostatus | ||||||
| Donor serostatus, N = 76 | ||||||
| Negative | 37 | 8 (22) | 1.0 | Reference | NA | |
| Positive | 41 | 11 (27) | 1.4 | 0.5-3.4 | NA | .51 |
| Recipient serostatus, N = 105 | ||||||
| Negative | 46 | 6 (13) | 1.0 | Reference | NA | |
| Positive | 57 | 15 (26) | 2.3 | 0.9-6.1 | NA | .07 |
| Acute lymphocytic leukemia | ||||||
| No | 112 | 18 (16) | 1.0 | Reference | NA | |
| Yes | 7 | 3 (43) | 2.7 | 0.8-9.2 | NA | .10 |
| HLA-A26, N = 117 | ||||||
| No | 111 | 18 (16) | 1.0 | Reference | NA | |
| Yes | 6 | 3 (50) | 3.6 | 1.0-12.2 | NA | .03 |
| HLA-DR2, N = 90 | ||||||
| No | 60 | 10 (17) | 1.0 | Reference | NA | |
| Yes | 30 | 9 (30) | 1.8 | 0.7-4.4 | NA | .19 |
| Cell source | ||||||
| PBSC | 31 | 8 (26) | 1.0 | Reference | NA | |
| Bone marrow | 88 | 13 (15) | 0.5 | 0.2-1.3 | NA | .15 |
| Donor buffy coat infusion | ||||||
| No | 87 | 18 (21) | 1.0 | Reference | NA | |
| Yes | 32 | 3 (9) | 0.5 | 0.1-1.5 | NA | .19 |
| Immunotherapy | ||||||
| No | 108 | 17 (16) | 1.0 | Reference | NA | |
| Yes | 11 | 4 (36) | 2.5 | 0.9-7.6 | NA | .08 |
| IL-2 therapy | ||||||
| No | 112 | 18 (16) | 1.0 | Reference | NA | |
| Yes | 9 | 4 (44) | 3.5 | 1.2-10.3 | NA | .02 |
| Conditioning regimen | ||||||
| Non-BUMELT | 107 | 16 (15) | 1.0 | Reference | NA | |
| BUMELT | 12 | 5 (42) | 3.6 | 1.3-9.8 | NA | < .01 |
| Transplantation year | ||||||
| 1980 to 1987 | 58 | 3 (5) | 1.0 | Reference | Reference | |
| 1988 to 1995 | 43 | 12 (28) | 5.2 | 1.5-18.6 | < .01 | |
| 1996 to 2002 | 18 | 6 (33) | 7.5 | 1.9-30.1 | < .01 | < .01 |
All P values are 2-sided. Variables listed include those with a P value ≤ .2 on univariable log-rank test. Level-specific P values were based on likelihood ratio tests from regression models. PBSC indicates peripheral blood stem cell; IL-2, interleukin-2; BUMELT, busulfan/melphalan/thiotepa; and NA, not applicable.